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Phoshpatidyl inositol 3’ OH kinase (PI3K) signaling and FOXO transcription 
factors play opposing roles at several B cell developmental stages. We show 
here abundant nuclear FOXO1 expression in the proliferative compartment of the 
germinal center (GC), its dark zone (DZ), and PI3K activity, downregulating 
FOXO1, in the light zone (LZ), where cells are selected for further differentiation. 
In the LZ, however, FOXO1 was expressed in a fraction of cells destined for DZ 
reentry. Upon FOXO1 ablation or induction of PI3K activity, GCs lost their DZ, 
owing at least partly to downregulation of the chemokine receptor CXCR4. 
Although this prevented proper cyclic selection of cells in GCs, somatic 
hypermutation and proliferation were maintained. Class switch recombination 







B cell differentiation is characterized by phases of cellular proliferation followed 
by periods during which the cells assume a resting state to further differentiate or 
persist in the system. An early period of proliferative expansion occurs in B cell 
progenitors in the bone marrow upon pre-B cell receptor expression (pre-BCR) 
(Reth and Nielsen, 2014). This event initiates a few rounds of division upon 
which the cells become resting small pre-B cells and differentiate into immature, 
BCR-expressing B cells. Upon transit into the peripheral immune system, some 
of these cells mature into resting peripheral B cells, which can persist for long 
periods of time. A second phase of cellular expansion occurs when mature B 
cells are driven into T-cell-dependent immune responses in a process called the 
germinal center (GC) reaction (Victora and Nussenzweig, 2012, Shlomchik and 
Weisel, 2012, Cyster, 2010, Zotos and Tarlinton, 2012, De Silva and Klein, 2015). 
In GCs, antigen-activated B cells undergo consecutive and cyclic phases of 
proliferation in the so-called GC dark zone (DZ), followed by a non-proliferative 
state in the GC light zone (LZ), where the cells are selected for DZ reentry or 
differentiation into memory B or plasma cells. Both pre-B cell differentiation in the 
bone marrow and the GC reaction in secondary lymphoid tissues involve genome 
editing in order to generate antibody diversity, through VDJ recombination in the 
former and somatic hypermutation (SHM) and class switch recombination (CSR) 
in the latter case. In both scenarios this is accompanied by stringent selection of 
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cells expressing appropriate antibody specificities. However, Recombination 
activating gene (RAG)-mediated VDJ recombination occurs in resting cells, 
whereas SHM takes place in proliferating GC cells, predominantly in the DZ. The 
site of CSR has not been firmly established. 
Earlier work has identified two antagonistic players in the control of proliferation 
versus differentiation in pre-B cell development. Here, proliferative expansion is 
dependent on activation of phosphatidyl inositol 3’ OH-Kinase (PI3K) signaling, 
which inhibits key transcription factors controlling cellular differentiation, namely 
Forkhead box transcription factors of the FOXO family, in keeping with the well-
established role of FOXO transcription factors as tumor suppressors (Paik et al., 
2007, Xie et al., 2012, Obrador-Hevia et al., 2012). Downregulation of PI3K 
activity and expression of FOXO transcription factors leads to the arrest of the 
cells in G1 phase and initiation of gene rearrangements at the IgL loci (Herzog et 
al., 2008). When the cells emerge from this differentiation process as mature, 
resting B cells, a BCR dependent “tonic” PI3K survival signal associated with 
downmodulation of FOXO1, becomes of vital importance (Srinivasan et al., 2009). 
Thus, at different stages of B cell differentiation and in a dose-dependent manner 
PI3K signaling can promote either cellular proliferation or survival, in accord with 
a large body of evidence obtained in other cell types (Engelman et al., 2006, 
Vanhaesebroeck et al., 2010, Thorpe et al., 2015). 
Activation of PI3K signaling through ablation of its antagonist Phosphatase and 
tensin homolog (Pten), or indeed Foxo1 deletion in mature B cells, interferes with 
CSR in T-cell-dependent antibody responses in vivo and activated B cells in vitro 
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(Suzuki et al., 2003, Omori et al., 2006, Dengler et al., 2008). Similarly, CSR is 
enhanced in activated B cells in culture by PI3K inhibition (Omori et al., 2006). 
There is suggestive evidence that these regulatory processes operate through 
the control of activation-induced deaminase (AID) expression by FOXO proteins. 
This earlier work implicates a regulatory role of FOXO1 in mature B cells but 
failed to address the interplay of PI3K signaling and FOXO1 in the GC reaction. 
In brief, and in stark contrast to the situation in pre-B and mature B cells, we here 
report a crucial role for FOXO1 in the formation and/or maintenance of the GC 
DZ where GC B cells classically proliferate and undergo SHM. Upon GC B-cell-
specific FOXO1 ablation or enforced PI3K activity, GCs developed, but lacked a 
discernible DZ. Although AID expression was not affected and SHM was only 
mildly reduced, CSR was largely ablated and the proper selection of high-affinity 
somatic antibody mutants was strongly disturbed. Together these findings 
indicate that the differential activation of PI3K and FOXO1 in mature B cells 
entering the GC reaction governs the sequence of proliferation, differentiation 




DZ and LZ GC B Cells Display Differential PI3K and FOXO1 Activity 
To study PI3K and FOXO1 activity in GCs, we immunized mice in which 
expression of a YFP reporter is initiated in GC B cells (C1-cre, R26 YFPstopfl) 
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(Casola et al., 2006), with sheep red blood cells (SRBCs) and analyzed the GC 
response in the spleens of these animals 10 days later. Immunofluorescence and 
intracellular flow cytometry analysis revealed polarized PI3K signaling pathway 
activity in GCs: pAKT (S473) expression, which serves as a readout of active 
PI3K, was selectively increased in LZ compared to DZ cells (Figures 1A and 1B). 
The specificity of the pAKT antibody was demonstrated in control experiments 
where a pAKT (S473) blocking peptide abrogated antibody binding. In contrast, 
FOXO1 localized predominantly to the nucleus of DZ cells and was hardly 
detectable in most cells of the LZ (Figure 1C). Co-staining for surface IgM 
showed that the vast majority of FOXO1-expressing cells were indeed GC B cells 
(Figure S1A). 
Thus, PI3K activity is largely restricted to B cells in the GC LZ; and the 
proliferating DZ B cells abundantly express nuclear FOXO1. 
 
GC B cells Can Be Detected in Conditional Mouse Models of Constitutive 
PI3K Activation or FOXO1 Ablation 
To directly address the functional role of PI3K signaling and FOXO1 in the GC 
reaction, we took advantage of a conditional mouse model that allowed the 
ablation of FOXO1 (Paik et al., 2007) and activation of a YFP reporter gene in 
early GC B cells. In parallel, we analyzed animals in which PI3K signaling was 
induced in GC B cells by expression of a constitutively active form of the catalytic 
PI3K subunit P110 (called P110*) coupled to GFP via an internal ribosome 
entry site (IRES) sequence (Srinivasan et al., 2009) or enhanced by cre-
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mediated ablation of Pten (Lesche et al., 2002), monitored by Rosa26-dependent 
YFP expression. 
At 10 and 20 days after SRBC immunization, GC B cells were identified by flow 
cytometry (CD19pos, B220pos, CD38low and FAShigh) in the spleens of C1-cre, 
R26 YFPstopfl (Control), C1-cre, R26 P110*stopfl (P110*), C1-cre, Ptenfl/fl, R26 
YFPstopfl (Ptenfl/fl) and C1-cre, Foxo1fl/fl, R26 YFPstopfl (Foxo1fl/fl) animals (Figure 
1D). The proportions of reporter-positive cells within the GC B cell gate as well as 
the percentages and absolute numbers of GC B cells in mutant (i.e., P110*, 
Ptenfl/fl and Foxo1fl/fl) compared to control animals did not reveal adverse effects 
of PI3K activation or Foxo1 deletion on the overall GC reaction (Figures 1E, 1F 
and Figures S1B and S1C). We also found that Foxo1 deletion in reporter gene-
expressing GC B cells was highly efficient (Figure S1D) and did not lead to 
significant upregulation of Foxo3 or Foxo4 mRNA (Figure S1E). Similarly, in 
Peyer’s patches GC B cell development or maintenance was not affected by 
PI3K activation or Foxo1 deletion, with detection of reporter-positive cells at the 
expected lower frequency (Figures 1G and 1H; (Casola et al., 2006)).  
Thus, constitutive PI3K activation or FOXO1 inactivation at an early stage of GC 
formation does not interfere with the generation of GC B cells. 
 
GC DZ Formation Depends on PI3K Inactivation and Nuclear FOXO1 
In contrast to the normal overall numbers of GC B cells, DZ and LZ 
compartmentalization was profoundly disturbed in the mutant animals both in 
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splenic GCs formed upon immunization and chronic GCs in Peyer’s patches 
(Figures 2A, 2B and 2C). CD86 and CXCR4 expression serve as established 
markers to define the two compartments by flow cytometry analysis (Victora et al., 
2012). In control animals DZ cells outnumbered LZ cells as previously described 
(Victora et al., 2010). In contrast, the splenic GC B cell compartment of 
immunized P110* and Foxo1fl/fl animals consisted solely of CXCR4low, CD86high 
LZ-like cells. In PTEN-deficient splenic GC B cells a DZ-like population 
(CXCR4high, CD86low) was detectable, but the majority of the cells expressed low 
amounts of CXCR4, reminiscent of LZ cells. The leaky phenotype in these 
animals was not due to cells that had escaped Pten deletion (Figure S2A). In 
Peyer’s patch GCs of Foxo1fl/fl and P110* mutants essentially all reporter-positive 
B cells exhibited a LZ-like phenotype (Figure 2C). 
The flow cytometry results were extended by gene expression profiling (GEP) 
analysis. In DZ and LZ cells from three immunized control animals (day 10 after 
SRBC injection) we identified 774 differentially regulated probe sets 
(corresponding to 584 genes) by a class comparison analysis (p<0.01; paired t 
test with random variance model; Table S2). The correct assignment of 
independent DZ and LZ samples (Victora et al., 2012) validated the relevance of 
these genes (Figure S2B). In a hierarchical cluster analysis based on the newly 
generated gene signature P110*-expressing and FOXO1-deficient GC B cells 
resembled more closely LZ than DZ cells (Figure 2D). Indeed, about 2/3 of the 
DZ-associated gene program (511 out of 774 probe sets corresponding to 206 
out of 584 genes) was lost in the mutant cells (Table S2), although their 
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expression profile was also clearly different from that of normal LZ cells (Figures 
S2C). For PTEN-deficient GC B cells, the small population of DZ-like cells may 
be responsible for their overall clustering more closely to DZ cells (Figure 2D). 
The supervised clustering was not exclusively dependent on the proliferative 
activity of the cells as removal of proliferation-associated genes (n = 106) from 
the signature did not change the clustering pattern (Figure S2D). Gene Set 
Enrichment Analysis (GSEA) showed that the normal DZ transcriptional program 
is highly enriched in FOXO1-proficient versus -deficient GC B cells (Figure 2E). 
Within the genes differentially regulated between these cells (Table S3) we 
identified factors controling the premature exit of GC B cells (Bach2, Prdm1, Irf4) 
(De Silva and Klein, 2015). In the absence of FOXO1, Bach2 was reduced and 
thus expression of the master regulator of plasma cell differentiation Prdm1 
increased. In vitro activation of mutant cells confirmed previous reports (Dengler 
et al., 2008) demonstrating increased plasma cell differentiation in FOXO1-
deficient B cells compared to controls (Figure S2E). As in LZ cells, Irf4 
expression was upregulated in FOXO1-ablated GC B cells, suggesting an 
additional mechanism of FOXO1-mediated GC maintenance control. In contrast, 
DNA-repair-associated genes (like Fanconi gene family members, Brca1 and 
Neil1) were downregulated. Some of these genes have previously been linked to 
GC programs like DNA editing and B cell expansion (Nguyen et al., 2014, Mori et 
al., 2009, Bjorkman et al., 2015). 
Histologically, in the GCs of P110* and Foxo1fl/fl animals, the network of activated 
follicular dendritic cells (FDCs), which precisely demarcates the LZ in control 
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animals, extended through the entire GC structure and was populated by GC B 
cells with nuclear FOXO1 being barely detectable (Figure 2F). These GCs thus 
lacked a histologically discernible DZ. The FDC network disturbance and 
absence of Foxo1-expressing cells was less pronounced in Ptenfl/fl animals, 
recapitulating the intermediate phenotype of PTEN deficiency observed in the 
flow cytometry and GEP analyses. 
Thus, the formation and/or maintenance of the GC DZ is dependent on FOXO1, 
and constitutive PI3K pathway activation or Foxo1 deletion results in defective 
GC architecture. 
 
GC B Cells with Enforced PI3K Signaling or FOXO1 Ablation Proliferate and 
Undergo SHM But Are Improperly Selected 
Although B cell proliferation in normal GCs is largely restricted to the DZ, we 
detected abundant cell proliferation in GCs from the mutant animals through 
staining for Ki67, a marker exclusively expressed by cycling cells (Figure 3A). 
Bromodeoxyuridine (BrdU) pulse labeling and flow cytometry analysis in control 
and mutant animals 10 days after SRBC immunization revealed incorporation in 
a large fraction of P110*-expressing and PTEN- or FOXO1-deficient GC B cells, 
while in GCs from control animals it was largely restricted to DZ cells (Figure 3B). 
Similarly, when we concomitantly induced proliferation and either P110* 
expression or Foxo1 deletion in B cells isolated from control and P110* or 
Foxo1fl/fl animals through exposure to anti-CD40 antibody or lipopolysaccharide 
(LPS) in combination with interleukin 4 (IL4), mutant cells divided to the same 
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extent as control cells in vitro (Figures 3C and S3A). The percentage of living 
cells over time was also similar in cultures of mutant and control cells (Figure 3D). 
Cell cycle analysis of anti-CD40+IL4- and LPS+IL4-stimulated B cells showed 
similar proportions of cells in G1, S and G2/M and sub-G1 for the different 
genotypes (Figures S3B and S3C). 
The proliferative activity of the GC B cells in the mutants was accompanied by 
SHM of their rearranged variable (V) region genes (Figures 4A and S4A), as 
monitored by sequence analysis of the intron downstream of JH4 (Jolly et al., 
1997) on days 10 and 20 after SRBC immunization. This was in accord with 
similar overall AID transcript and protein expression in mutant and control cells, 
exceeding more than 50-fold those in non-GC B cells (Figures 4B and 4C). 
Notably, however, the load of somatic mutations was consistently lower in the 
mutants compared to the controls, both in terms of numbers of mutations per 
mutated sequence and the fraction of unmutated sequences. Among the mutants, 
the PTEN-deficient cells were intermediate in terms of somatic mutations 
between the P110* and Foxo1fl/fl mutants. 
To directly address clonal recruitment and affinity maturation in PI3K-activated 
and FOXO1-deficient GC B cells we analyzed the response of mutant mice to the 
hapten 4-hydroxy-3-nitro-phenylacetyl (NP) coupled to chicken gamma globulin 
(CGG). In wild-type mice, this response is dominated by Ig+ antibodies 
expressing the V186.2 IgH chain, in which the W33L mutation serves as a 
marker for affinity selection (Allen et al., 1987). However, in P110* and Foxo1fl/fl 
animals the strong selection of Ig-expressing cells in the GC B cell pool after NP 
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antigen exposure was not detectable (Figure 4D), with a similar (low) frequency 
of Ig+ B cells in their GCs as in the overall population of follicular B cells (Figure 
S4B). Similarly, the percentage and absolute number of hapten-binding GC B 
cells was significantly reduced in mutant animals compared to controls (Figure 
4E and S4C). Within this cell population, IgG1-expressing cells were almost 
absent in the mutants (Figure S4D) indicating defective CSR in the absence of 
Foxo1 expression (see below). Because of the difference in the clonal 
composition of NP-induced GCs in control and mutant animals we decided to 
analyze the VH186.2 mutation load in individual hapten-binding GC B cells by 
single cell sorting and cDNA sequencing (Kaji et al., 2012). Non-synonymous 
and synonymous VH186.2 gene mutations were significantly reduced in mutant 
GC B cells compared to controls (Figure S4E), recapitulating the SHM defect 
after SRBC immunization (Figure 4A). However, W33L mutations of VH186.2 
were clearly detectable in P110*-expressing or FOXO1-deficient GC B cells 
(Figure 4F), indicative of selection of high-affinity cells.  
The abnormal cellular selection and reduced accumulation of somatic mutations 
in PI3K-pathway-activated and FOXO1-deficient GC B cells over time was in 
agreement with the observation that these cells failed to express the chemokine 
receptor CXCR4 (Figure 2A), a protein essential for GC DZ formation and 
suggested to be required for the proper selection of somatic antibody mutants in 
the GC reaction (Allen et al., 2004, Bannard et al., 2013). An essential step in the 
selection of cells expressing high-affinity antibody mutants is the recruitment of 
LZ cells back into the GC DZ (Victora et al., 2010, Oprea and Perelson, 1997, 
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Gitlin et al., 2014). In previous work, we and others had identified these cells as a 
minority of LZ B cells, namely those expressing the transcription factor c-MYC 
(Calado et al., 2012, Dominguez-Sola et al., 2012). Analyzing the c-MYC+ B cells 
in the GC LZ of immunized control mice by immunofluorescence, we found that 
around 60% of these cells were positive for FOXO1, in striking contrast to the 
paucity of FOXO1+ cells in the GC LZ (Figures 5A and 5B). These findings 
suggest that it is in the c-MYC+ cells in the LZ that the FOXO1-dependent DZ 
transcriptional program is initiated. 
 
CSR Is Blocked in LZ-like GC B Cells with Enforced PI3K Signaling or 
FOXO1 Ablation 
In contrast to SHM in PI3K and Foxo1 mutant GC B cells, we hardly found 
immunoglobulin isotype-switched cells in these cell populations. In the SRBC 
response, splenic GC B cells underwent CSR predominantly to express IgG1 and 
IgG2, but GC cells expressing these isotypes at the cell surface were strongly 
reduced in the spleens of immunized mutant animals (Figures 6A, 6B and S5A). 
There was also a profound reduction of IgA-expressing GC B cells in the Peyer’s 
patches of the mutants (Figure 6C). In contrast, switching to IgG3, minor in the 
anti-SRBC response, seemed hardly affected (Figure S5B). 
CSR involves a synapse between the recombining switch regions and the 
initiation of transcription from promoters upstream of the switch regions involved. 
The corresponding so-called germ-line transcripts (GLTs) support the switch 
region targeting of AID to produce staggered single-strand DNA breaks through 
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which switch region recombination is accomplished (Chaudhuri et al., 2007, Pavri 
and Nussenzweig, 2011). As AID expression appeared undisturbed in the 
mutants (Figures 4B and 4C) and the downstream machinery of CSR seemed 
intact given the undisturbed switching to IgG3 (Figure S5B), we analyzed 
whether FOXO1 activity was required to regulate AID targeting to switch regions. 
Therefore, GLT transcription for the various isotypes in GC B cells from 
immunized mutant and control animals was assessed and GLT expression was 
compared to those of post-switch transcripts (PSTs) in the same samples. The 
results indicated similar or even higher GLTs in mutants compared to controls for 
the upstream region of S (Figure 6D). In contrast, 1 GLT expression tended to 
be reduced in all mutants (Figure 6E) and fewer 2b GLTs were detectable in 
P110* GC B cells compared to controls (Figure S5C), although the data exhibited 
substantial scatter in several instances. 3 GLTs were not diminished in the 
mutants (Figure S5D). The PSTs of 1, 2b and 3 in the mutant and control cells 
were in accord with the percentage of switched GC B cells as detected by flow 
cytometry (Figures 6E, S5C and S5D), suggesting a CSR defect upstream of 
DNA recombination in PI3K-activated or Foxo1-deleted GC B cells. In a second, 
more direct approach, we addressed whether PI3K activation or Foxo1 deletion 
affected the targeting of the switch regions by AID, through sequence analysis of 
the DNA immediately upstream of such regions. This approach is based on the 
earlier discovery that in the switching process these stretches of DNA 
accumulate footprints of AID activity in the form of somatic mutations (Petersen 
et al., 2001, Nagaoka et al., 2002, Reina-San-Martin et al., 2003). Extensive 
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somatic mutation was indeed evident upstream of S in the controls, but it was 
clearly reduced in the mutants, most prominently in FOXO1-ablated cells (Figure 
7A). In all cases, the cytosine-targeted mutations on both the transcribed and 
non-transcribed strands demonstrated a strong AID hotspot sequence motif 
preference (i.e., AGCT, mutated base underlined) (Figure 7B), and the 
distribution of the mutations along the DNA was similar to earlier results (Figure 
7C) (Xue et al., 2006). With respect to downstream switch regions, we detected 
substantial numbers of mutated sequences only for S1, with a similar clear 
reduction of mutations in the various mutant cells (Figure S6). Together, these 





PI3K signaling and the expression of FOXO transcription factors, which PI3K 
activity antagonizes, have been shown to play opposing roles in pre-B cell 
development, with PI3K controlling proliferative expansion and FOXO1 playing a 
crucial role during pre-B cell differentiation through IgL chain gene 
rearrangements (Herzog et al., 2008). The results reported here establish distinct 
roles for PI3K and FOXO1 activity for a later phase of B cell expansion, 
diversification, and selection, namely the GC reaction. Paradoxically, however, in 
this case it is FOXO1 that was highly expressed and active in the proliferative 
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compartment (i.e., the GC DZ), and PI3K activity was largely restricted to the LZ 
where the cells are selected on the basis of antibody affinity for reentry into the 
DZ or differentiation into memory B or plasma cells. Although FOXO1 expression 
in highly proliferative cells is at odds also with its well-established role as a tumor 
suppressor (Paik et al., 2007, Xie et al., 2012, Obrador-Hevia et al., 2012), recent 
evidence attests to its ability to function as an oncogene in certain cellular 
contexts (Sykes et al., 2011, Naka et al., 2010). Of particular relevance in 
connection to the GC reaction are recurrent activating mutations of FOXO1 in GC 
B-cell-derived lymphomas, where the mutant FOXO1 is resistant to PI3K 
inactivation (Trinh et al., 2013). It remained unclear from this work, however, 
whether FOXO1 mutations and PI3K activation coexisted in the same cells. That 
this scenario is indeed possible is strongly supported by the detection of similar 
Foxo1 mutations in a mouse model of Burkitt lymphoma, where constitutive PI3K 
activation cooperates with c-MYC overexpression in tumor development (Sander 
et al., 2012). It remains to be clarified how the concerted action of the usually 
antagonistic principles of PI3K and FOXO1 activation can drive 
lymphomagenesis. 
 In the GC reaction, the role of FOXO1 in the proliferating DZ cells was 
clearly distinct from the above scenario in that the PI3K pathway was largely 
downregulated in these cells. Therefore, if FOXO1 plays a role in the control of 
proliferation in these cells, it would be in concert with other signaling or 
transcriptional regulators. However, the genetic experiments of ablating FOXO1 
or enforcing PI3K activity in GC B cells shed light on these considerations in that 
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these genetic manipulations preclude the formation of a GC DZ, but in contrast 
left basic features of the GC reaction intact which have been traditionally 
considered hallmarks of the GC DZ. Thus, we still observed extensive 
proliferative activity in GCs upon Foxo1 deletion or enforced PI3K activity, and 
SHM of rearranged immunoglobulin V region genes was clearly active in the 
mutant cells, although the load of somatic mutations lagged behind that 
accumulating in wild-type GC cells. Thus, neither cellular expansion nor SHM in 
GCs requires a GC DZ or FOXO1 activity.  
 On the other hand, as our study addressed B-cell-autonomous functions 
of FOXO1, we have to conclude that this transcription factor plays a critical role 
in programing GC B cells to adopt a gene expression program that impinges on 
them and their cellular environment such that a GC DZ is formed. Our gene 
expression and gene set enrichment analysis suggests that FOXO1 indeed 
directly or indirectly controls a major part of the gene expression program that 
distinguishes DZ from LZ cells, even when cell-cycle-related genes are excluded 
from the analysis. While apart from some well-known candidate genes, the 
identification of the signaling and transcriptional pathways regulated by FOXO1 
in the GC DZ (including its possible involvement in the control of phosphatase 
activity that limits BCR-mediated selection in most cycling GC B cells (Khalil et al., 
2012)) will have to await functional experiments. 
One critical downstream player emerging from the analysis is the chemokine 
receptor CXCR4. As a characteristic marker of B cells in the GC DZ, CXCR4 
expression is entirely lost in the PI3K and Foxo1 mutants, in line with evidence in 
	 19
the literature that FOXO1 can directly or indirectly control CXCR4 expression 
(Potente et al., 2005, Dubrovska et al., 2012). Work by Bannard et al. (Bannard 
et al., 2013) has suggested that CXCR4 controls DZ reentry of LZ cells. 
Consequently, CXCR4 deficiency leads to an inability of GC B cells to reside in 
the GC DZ and thus to properly participate in the program of mutation and 
selection in GCs. Accordingly, they found impaired SHM in these cells, similar to 
what we find in the PI3K and Foxo1 mutants. That clonal recruitment and 
selection of high-affinity cells in GCs is profoundly disturbed in the mutant mice 
became evident from the analysis of the anti-NP response, which is dominated in 
wild-type mice by Ig+ antibodies expressing the V186.2 VH gene. In the mutants, 
such cells represented a minority of the GC B cell population, and the number of 
hapten-binding cells was drastically reduced. Thus, although sequence analysis 
demonstrated some selection for cells expressing high-affinity NP-binding 
receptors, this process is clearly hampered in the mutants. While the details of 
this deficiency remain to be worked out, it seems likely that the absence of 
distinct consecutive phases of clonal expansion and selection of non-cycling cells 
in the mutant GCs contributes to this phenotype. Still, the principle that B cell 
maintenance requires BCR expression seems to hold in the GC B cells of the 
mutants, as we did not observe an accumulation of stop codons generated by 
somatic mutations in the IgH chain V region genes isolated from those cells 
(unpublished data). 
 In contrast to SHM, CSR was severely hampered in the PI3K and Foxo1 
mutants. Earlier work has identified FOXO1 as an essential regulator of CSR, but 
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its activity has been ascribed to the control of AID expression, as studied in 
mitogen and IL4 activated naive B cells in vitro (Dengler et al., 2008). We have 
reproduced these results in our own experiments (unpublished data), but found 
that PI3K activation or Foxo1 deletion selectively in GC B cells in vivo did not 
affect AID transcript or protein expression, while still abolishing CSR. The 
detection of reduced Aicda transcripts in ex vivo GC B cells in which Foxo1 
deficiency had been initiated before the cells had encountered antigen (Dengler 
et al., 2008) exemplifies the need for developmental-stage-specific ablation of the 
transcription factor to study its physiologic function. Similarly, the reduced IgG3 
serum concentration in CD19-cre, Ptenfl/fl animals after antigen stimulation 
(Suzuki et al., 2003) might be due to an altered cellular program induced upon 
PI3K activation in B cells before they enter the GC reaction. Analyzing early 
processes in CSR, namely pre-switch transcription and AID-mediated somatic 
hypermutation of DNA stretches adjacent to switch regions in the IgH locus, we 
have provided evidence that FOXO1 plays a critical, though possibly not 
exclusive, role in GC B cells in the initiation of CSR, at a stage prior to the 
introduction of AID-mediated DNA breaks. This concept is further supported by 
earlier experiments in which CSR is still markedly inhibited in in vitro-activated 
PTEN-deficient B cells retroviraly transduced with Aicda (Omori et al., 2006). The 
present results raise the possibility that FOXO1 is involved in the assembly of a 
pre-switch synaptic complex (Wuerffel et al., 2007, Zarrin et al., 2007, Gostissa 
et al., 2014) in which the recombining switch regions are brought together to 
enable efficient AID targeting. Interestingly, in the case of Sμ this was 
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independent of switch region transcription. The strong reduction of isotype 
switching to IgG1 and IgA in the spleens and Peyer’s patches, respectively, of 
the mutant animals, in the presence of normal IgG3 CSR in mutant splenic GC B 
cells is indicative of switch region and perhaps context-dependent functions of 
the PI3K pathway and FOXO1 in the control of CSR. Indeed, in the 
accompanying paper, Dominguez-Sola et al. (Dominguez-Sola et al., 2015) 
identify FOXO1 binding in enhancer regions mediating intra-chromosomal 
interactions at the IgH locus (Kieffer-Kwon et al., 2013) in human tonsillar B cells 
by ChIP-Seq experiments. Another as yet unresolved question, which our 
experiments indirectly address, is the nature of the cells in the GC where CSR 
takes place. Given that CSR in GCs is thought to be induced by T-cell-dependent 
B cell activation in the GC LZ (where most cells do not express FOXO1) and was 
not affected in CXCR4-deficient GC B cells (Bannard et al., 2013) (which do not 
reside in the GC DZ), we speculate that it may occur in the small population of c-
MYC-expressing B cells in the LZ that are candidates for DZ reentry (Calado et 
al., 2012, Dominguez-Sola et al., 2012) and for a fraction of which our data 






Mice and immunization 
C1-cre; R26 P110*stopfl; Foxo1fl; Ptenfl and R26 YFP stopfl alleles have been 
described (Casola et al., 2006, Calado et al., 2012, Srinivasan et al., 2009, Paik 
et al., 2007, Lesche et al., 2002). Animals were bred in our mouse colonies at the 
Immune Disease Institute (Boston) and Max Delbrück Center (Berlin). For T cell–
dependent immunization, 8- to 12-week-old mice were injected intravenously with 
1x109 SRBCs (Cedarlane) in PBS or intraperitoneally with 100g alum-
precipitated NP-CGG (Sigma). Animals were analyzed at day 10 or day 20 after 
immunization. All animal care and procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of Harvard University and the Immune 
Disease Institute (03341), and the LaGeSo Berlin (G0273/11). 
 
BrdU incorporation experiments 
Animals were immunized with SRBC and 10 days later 1mg BrdU (BD 
PharMingen) was intraperitoneally injected. 3 hours after BrdU injection the 
animals were sacrified and splenocytes were analyzed by flow cytometry for 
BrdU incorporation (BrdU Flow Kit; BD PharMingen). 
 
in vitro B cell activation  
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To induce cre recombinase expression and B cell activation CD43 depleted 
(Miltenyi) splenic B cells of control and mutant animals were cultured in the 
presence of 1µg/ml of anti-CD40 antibody (HM40-3, eBioscience) or 20µg/ml of 
LPS (Sigma) and 25ng/ml of IL4 (R&D Systems) for a maximum of 5 days. At 
day 0 cells were labeled with CellTrace Violet (LifeTechnologies) according to the 
manufacturer’s protocol. For cell cycle analysis in vitro activated B cells were 
stained with propidium iodide (Sigma) after RNase A (Sigma) treatment.  
 
Flow Cytometry and cell sorting 
A detailed list of the antibodies is provided in Supplemental Information. In the 
analysis of hapten binding 4-hyroxy-3-nitro-5-iodophenylacetyl (NIP) was used 
instead of NP, because of its 10 times higher affinity to Ig+ anti-NP antibodies 
(Allen et al., 1987).  
 
Immunofluorescence analysis 
Spleen sections from immunized control and mutant animals were frozen in OCT 
(Sakura Finetek) and liquid nitrogen. Cryo-sections (7µm) were fixed with 4% 
paraformaldehyde for 15 minutes at room temperature (RT). Afterwards, the 
slides were washed with PBS and incubated with PBS/0.25% TritonX-100 for 15 
minutes at RT (permeabilization). For blocking of unspecific antibody binding the 
sections were incubated with PBS/3%BSA/0.2% TritonX-100 for 1 hour at RT. 
The tissues were stained for 1 hour at RT (or overnight at 4°C) with anti-FOXO1 
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antibody (C29H4, Cell Signaling), anti-c-MYC Dylight 488 (Y69, Abcam), anti-
CD21/CD35 APC (7G6, BD PharMingen), anti-BCL6 PE (GI191E, eBioscience), 
anti-Ki67 (MIB-5, Dako), anti-IgM APC (II/41, BD PharMingen), anti-FDC-M2 
Alexa 546, and anti-IgD Cy5. Secondary goat-anti rabbit IgG-Alexa 488 and 546 
antibodies (Invitrogen) were used if necessary. Nuclei were stained with DAPI. 
The sections were analyzed on a KEYENCE microscope. 
 
Quantitative RT-PCR  
Total RNA from sorted cells was extracted using the AllPrep DNA/RNA Kit 
(QIAgen) and cDNA was synthesized using random hexamer primers and the 
Thermoscript RT-PCR system (Invitrogen). For quantitative RT-PCR we used 
Power SYBR Green, followed by analysis with the StepOnePlus system (Applied 
Biosystems). Samples were assayed in triplicate and messenger abundance was 
normalized to that of Hprt. Primer sequences are provided in the Table S1. 
 
Mass spectrometry based protein quantification 
Proteins extracted from GC B cells of control and mutant animals (day 10 after 
SRBC immunization) were digested and subjected to online liquid 
chromatography-tandem mass spectrometry (nanoLC-MS/MS) analysis. A 
detailed description is provided in Supplemental Information. 
 
IgH somatic mutation analysis 
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Genomic DNA was prepared from sorted GC B cells of SRBC immunized animals 
and the analysis was performed using published procedures (Jolly et al., 1997, 
Xue et al., 2006). Sequence analysis of the IgH region of NP specific GC B cells 
was performed as previously described (Kaji et al., 2012). Primer sequences are 
provided in the Table S1. 
 
Statistical analysis 
Data were analyzed using unpaired two-tailed student’s t-test, Wilcoxon-Mann-
Whitney test and Fisher's exact test, a p value 0.05 was considered significant.  
 
Gene expression profiling and data analysis 
Gene expression profiling was performed on GC B cell samples using Affymetrix 
GeneChip Mouse Genome 430 2.0 Arrays according to the manufacturer’s 
recommendations (Affymetrix).  
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Figure 1. Compartmentalized Expression of Nuclear FOXO1 and pAKT in GCs, 
and Normal GC B Cell Frequencies in Genetically Modified Animals. 
(A) Detection of pAKT (S473) in splenic DZ and LZ GC B cells of immunized 
control animals (day 10 after SRBC administration) by intracellular flow cytometry 
analysis. CD86 and CXCR4 surface marker stainings were included to define DZ 
(CD86loCXCR4hi) and LZ (CD86hiCXCR4lo) cells. After fixation and 
permeabilization, splenocytes were incubated with pAKT (S473) antibody 
(antibody) or rabbit IgG (isotype control) or pAKT (S473) antibody plus pAKT 
(S473) blocking peptide (blocking peptide). 
(B) Summary and quantification of flow cytometry data as shown in (A). Each 
symbol represents an individual animal; horizontal lines indicate the mean. 
(C) Immunofluorescence analysis of spleen sections from immunized control 
animals (day 10 after SRBC injection). Antibodies detecting FOXO1, FDC-M2 
(which delineates the activated FDC network) and IgD (which marks the follicular 
B cell compartment) were used. Dashed lines delineate DZ and LZ. Two 
individual animals were analyzed. Scale bars represent 25 μm. Graph: Summary 
and quantification of immunofluorescence analysis (presented as in B). Each 
symbol represents an individual GC. 
(D) Representative flow cytometry analysis of splenocytes from immunized 
control and mutant animals (P110*; Ptenfl/fl; Foxo1fl/fl) at day 10 after SRBC 
	 32
injection. Reporter gene expression was used to monitor cre-mediated 
recombination. Cells were consecutively gated on viable (TO-PRO-3– or PI–) 
lymphocytes, B cells (B220+CD19+) and GC B cells (CD38loFAShi). Numbers 
adjacent to outlined areas indicate the percentage of cells. 
(E and F) Summary and quantification of flow cytometry data of reporter+ (E) and 
GC B (F) cells as shown in (D). Each symbol represents an individual animal; 
horizontal lines indicate the mean. 
(G and H) Summary and quantification of flow cytometry data of reporter+ (G) 
and GC B (H) cells detected in Peyer’s patches (presented as in E and F). 
NS, not significant (p > 0.05); *p ≤ 0.05 and **p ≤ 0.001 (Wilcoxon-Mann-Whitney 
test). See also Figure S1. 
 
Figure 2. PI3K-Pathway-Activated or Foxo1-Deleted GC B Cells Express LZ-like 
Genes and Populate GCs Lacking a DZ. 
(A) Representative flow cytometry analysis of splenocytes from immunized 
control and mutant animals (P110*; Ptenfl/fl; Foxo1fl/fl) at day 10 after SRBC 
injection. Cells were consecutively gated as in Figure 1D. 
(B) Summary and quantification of flow cytometry data as shown in (A). Each 
symbol represents an individual animal; horizontal lines indicate the mean. 
(C) Summary and quantification of Peyer’s patches data (presented as in B). 
(D) Hierarchical cluster analysis based on LZ and DZ signature genes (n = 774 
probe sets corresponding to n = 584 unique genes). DZ (CD86loCXCR4hi) and LZ 
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(CD86hiCXCR4lo) cells of control animals and total GC B cells (CD38loFAShi) of 
P110*, Ptenfl/fl and Foxo1fl/fl samples were analyzed. Log2 transformed and 
mean-centered gene expression data are color coded. 
(E) Gene set enrichment analysis (GSEA) showing a highly significant 
enrichment (p < 0.001) of the normal DZ transcriptional program in FOXO1-
proficient GC B cells (left: positive association of DZ-upregulated genes with 
FOXO1-proficient cells; right: positive association of LZ-upregulated genes with 
FOXO1-deficient cells). 
(F) Immunofluorescence analysis of spleen sections from immunized control and 
mutant animals (day 10 after SRBC administration). The same antibodies as in 
Figure 1C were used. Dashed lines delineate GCs. Two individual animals per 
genotype were analyzed. Scale bars represent 25 μm. 
NS, not significant (p > 0.05); *p ≤ 0.05 and **p ≤ 0.001 (Wilcoxon-Mann-Whitney 
test). See also Figure S2 and Table S2. 
 
Figure 3. Normal Proliferation and Survival of PI3K-Pathway-Activated or Foxo1-
Deleted GC and In Vitro Activated B Cells. 
(A) Immunofluorescence analysis of spleen sections from immunized control and 
mutant animals (day 10 after SRBC injection). Antibodies detecting IgD 
(expressed on follicular B cells), BCL6 (expressed by GC B cells) and Ki67 were 
used. Two individual animals per genotype were analyzed. Scale bar represents 
25 μm. 
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(B) Summary and quantification of BrdU incorporation in splenic GC B cells of 
immunized control and mutant animals (day 10 after SRBC injection and 3 hr 
after BrdU application). LZ and DZ cells of control animals were included in the 
analysis. Each symbol represents an individual animal; horizontal lines indicate 
the mean. 
(C) CellTrace analysis in anti-CD40+IL4-stimulated B cells of various genotypes 
(Control, solid grey line; P110*, blue line; Foxo1fl/fl, black line). Day 0 (d0) 
corresponds to the CellTrace labeling efficiency of the B cells before stimulation. 
At days 2, 3 and 4 after stimulation, only reporter-positive cells were analyzed. 
Data are representative of two independent experiments. 
(D) Percentage of living B cells after anti-CD40+IL4 stimulation at indicated time 
points. Data are normalized to the number of cells at day 0 (input). Data are 
representative of two independent experiments; horizontal lines indicate the 
mean. 
NS, not significant (p > 0.05); *p ≤ 0.05 and **p ≤ 0.001 (Wilcoxon-Mann-Whitney 
test). See also Figure S3. 
 
Figure 4. Reduced Mutation Load in the Immunoglobulin Genes of PI3K-
Pathway-Activated or Foxo1-Deleted GC B cells and Impaired Selection of NP-
Specific GC B Cells in Mutant Animals. 
(A) JH4 intron mutation analysis in splenic GC B cells of SRBC-injected animals 
at day 10 (d10) and day 20 (d20) after immunization. Non-GC B cells of control 
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animals were included in the analysis. At least two individual animals per 
genotype were analyzed. Each symbol represents an individual sequence; red 
horizontal lines indicate the mean. 
(B) Quantitative RT-PCR analysis of Aicda expression in non-GC and GC B cells 
of control and mutant animals (day 10 after SRBC immunization). Results are 
normalized to those of non-GC B cells and are presented relative to expression 
of the control gene Hprt. Each symbol represents an individual animal; horizontal 
lines indicate the mean. 
(C) Label-free quantification of the ILLPLYEVDDLR peptide derived from AID 
protein in control and mutant GC B cells by LC-MS/MS. AID intensity is 
normalized to the intensity of HPRT. Each symbol represents an individual 
sample; horizontal lines indicate the mean. Note: the peptide was not detectable 
in one out of three Foxo1 fl/fl samples. 
(D and E) Summary and quantification of flow cytometry data of Ig+ (D) and 
hapten-binding reporter+ GC B (E) cells detected in the spleens of immunized 
control and mutant animals (day 20 after NP-CGG immunization). Each symbol 
represents an individual animal; horizontal lines indicate the mean. 
(F) Pie charts showing the distribution of clones carrying the W33L mutation in 
VH186.2 for each genotype assayed, with the number of individual clones 
analyzed shown at the center of each pie chart. The assay was performed by 
PCR and sequencing using the cDNA of single splenic GC B cells isolated from 
control and mutant mice at day 20 after NP-CGG immunization. Two individual 
animals per genotype were analyzed. 
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NS, not significant (p > 0.05); *p ≤ 0.05 and **p ≤ 0.001 (Wilcoxon-Mann-Whitney 
test). See also Figure S4.  
 
Figure 5. Co-expression of c-MYC and FOXO1 in a Subset of LZ Cells.  
Two examples of spleen sections from immunized control animals (day 10 after 
SRBC immunization) analyzed by immunofluorescence. Antibodies detecting 
CD21/CD35 (expressed by the FDC network) (A), c-MYC (A and B) and FOXO1 
(A and B) were used. White lines delineate DZ and LZ. Two individual animals 
were analyzed. Scale bars represent 25 μm (B) Graph: Summary and 
quantification of immunofluorescence analysis. Each symbol represents an 
individual GC; horizontal line indicates the mean.  
 
Figure 6. CSR Is Controlled by the PI3K Pathway and FOXO1 in GC B Cells. 
(A) Representative flow cytometry analysis of splenocytes from immunized 
control and mutant animals (P110*; Ptenfl/fl; Foxo1fl/fl) at day 10 after SRBC 
injection. Cells were consecutively gated as in Figure 1D. 
(B) Summary and quantification of flow cytometry data as shown in (A). Each 
symbol represents an individual animal; horizontal lines indicate the mean. 
(C) Summary and quantification of Peyer’s patches data (presented as in B). 
(D) Quantitative RT-PCR analysis of μ germline transcript (GLT) expression in 
splenic GC B cells of control and mutant animals (day 10 after SRBC 
immunization). Non-GC B cells of control animals were included in the analysis. 
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Results are normalized to those of control cells and are presented relative to 
expression of the control gene Hprt. Each symbol represents an individual 
animal; horizontal lines indicate the mean. 
(E) Quantitative RT-PCR analysis of γ1 GLT (left) and post-switch transcript 
(PST; right) expression in splenic GC B cells of control and mutant animals 
(presented as in D). 
NS, not significant (p > 0.05); *p ≤ 0.05 and **p ≤ 0.001 (Wilcoxon-Mann-Whitney 
test). See also Figure S5. 
 
Figure 7. PI3K Activation or Foxo1 Deletion in GC B Cells Interferes with CSR 
Initiation. 
(A) Pie charts showing the distribution of clones carrying the indicated number of 
mutations in the 820 base pair region immediately upstream of the μ switch (Sμ) 
region for each genotype assayed, with the number of reads analyzed shown at 
the center of each pie chart. The assay was performed by PCR and sequencing 
using the genomic DNA of splenic GC B cells isolated from control and mutant 
mice at day 10 after SRBC immunization. Non-GC B cells 
(B220+CD19+CD38hiFASlo) were included in the analysis as a negative control. 
Data of two animals per genotype are summarized. 
(B) For all C:G-targeted somatic mutations in (A), the sequence context of the 
mutated C base was analyzed for each genotype (non-GC B cells were excluded 
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from analysis). The percentage of mutations at A:T base pairs versus G:C base 
pairs is shown for each genotype. 
(C) Distribution of Sμ-associated somatic mutations shown in (A). 
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Control (92 reads; 122 mutations)
P110* (95 reads; 80 mutations)
Pten fl/fl (89 reads; 58 mutations)
Foxo1 fl/fl (241 reads, 91 mutations)
Non-GC (93 reads; 7 mutations)
